Soheil Meshinchi
Overview
Explore the profile of Soheil Meshinchi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
221
Citations
7773
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Buteyn N, Burke C, Sartori V, Deering-Gardner E, DeBruine Z, Kamarudin D, et al.
bioRxiv
. 2024 May;
PMID: 38798454
Despite decades of research, acute myeloid leukemia (AML) remains a remarkably lethal malignancy. While pediatric AML (pAML) carries a more favorable prognosis than adult AML, the past 25 years of...
12.
van Dijk A, Hoff F, Qiu Y, Hubner S, Go R, Ruvolo V, et al.
Cancers (Basel)
. 2024 Apr;
16(8).
PMID: 38672531
The addition of the proteasome inhibitor bortezomib to standard chemotherapy did not improve survival in pediatric acute myeloid leukemia (AML) when all patients were analyzed as a group in the...
13.
Uechi L, Vasudevan S, Vilenski D, Branciamore S, Frankhouser D, OMeally D, et al.
NPJ Syst Biol Appl
. 2024 Mar;
10(1):32.
PMID: 38527998
Acute myeloid leukemia (AML) is prevalent in both adult and pediatric patients. Despite advances in patient categorization, the heterogeneity of AML remains a challenge. Recent studies have explored the use...
14.
Pemmaraju N, Cuglievan B, Lasky J, Kheradpour A, Hijiya N, Stein A, et al.
EJHaem
. 2024 Feb;
5(1):61-69.
PMID: 38406504
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) predominantly occurs in adults ≥60 years old; 10-20% of cases are pediatric or adolescent/young adult (AYA) patients. Tagraxofusp (TAG, Elzonris) is the only approved...
15.
Abla O, Ries R, Triche Jr T, Gerbing R, Hirsch B, Raimondi S, et al.
Blood Adv
. 2024 Feb;
8(8):2005-2017.
PMID: 38306602
MLLT10 gene rearrangements with KMT2A occur in pediatric acute myeloid leukemia (AML) and confer poor prognosis, but the prognostic impact of MLLT10 in partnership with other genes is unknown. We...
16.
Menssen A, Hudson C, Alonzo T, Gerbing R, Pardo L, Leonti A, et al.
Haematologica
. 2024 Feb;
109(10):3182-3193.
PMID: 38299667
As curative therapies for pediatric acute myleoid leukemia (AML) remain elusive, identifying potential new treatment targets is vital. We assessed the cell surface expression of CD74, also known as the...
17.
Tarlock K, Gerbing R, Ries R, Smith J, Leonti A, Huang B, et al.
Blood Adv
. 2024 Jan;
8(9):2094-2103.
PMID: 38295280
We sought to define the cooccurring mutational profile of FLT3-ITD-positive (ITDpos) acute myeloid leukemia (AML) in pediatric and young adult patients and to define the prognostic impact of cooperating mutations....
18.
Janssens D, Duran M, Otto D, Wu W, Xu Y, Kirkey D, et al.
bioRxiv
. 2024 Jan;
PMID: 38234854
Chromosomal translocations involving the ( ) locus generate potent oncogenic fusion proteins (oncoproteins) that disrupt regulation of developmental gene expression. By profiling the oncoprotein-target sites of 36 broadly representative -rearranged...
19.
Shastri V, Chauhan L, Gbadamosi M, Alonzo T, Wang Y, Aplenc R, et al.
Clin Cancer Res
. 2024 Jan;
31(5):890-898.
PMID: 38197878
Purpose: Comprehensive pharmacogenomics (PGx) evaluation of calicheamicin pathway to identify predictive PGx markers of response to gemtuzumab ozogamicin (GO) treatment in acute myeloid leukemia (AML). Experimental Design: SNPs in DNA...
20.
Lambo S, Trinh D, Ries R, Jin D, Setiadi A, Ng M, et al.
Cancer Cell
. 2023 Nov;
41(12):2117-2135.e12.
PMID: 37977148
Pediatric acute myeloid leukemia (pAML) is characterized by heterogeneous cellular composition, driver alterations and prognosis. Characterization of this heterogeneity and how it affects treatment response remains understudied in pediatric patients....